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Abstract
Objective: Immune changes occurring after primary HIV infection (PHI) have a pivotal relevance. Our objective was to
characterize the polyfunctionality of immune response triggered by PHI, and to characterize immune activation and
regulatory T cells, correlating such features to disease progression.
Patients and Methods: We followed 11 patients experiencing PHI for 4 years. By polychromatic flow cytometry, we studied
every month, for the first 6 months, T lymphocyte polyfunctionality after cell stimulation with peptides derived from HIV-1
gag and nef. Tregs were identified by flow cytometry, and T cell activation studied by CD38 and HLA-DR expression.
Results: An increase of anti-gag and anti-nef CD8+ specific T cells was observed 3 months after PHI; however, truly
polyfunctional T cells, also able to produce IL-2, were never found. No gross changes in Tregs were present. T lymphocyte
activation was maximal 1 and 2 months after PHI, and significantly decreased in the following period. The level of activation
two months after PHI was strictly correlated to the plasma viral load 1 year after infection, and significantly influenced the
length of period without therapy. Indeed, 80% of patients with less than the median value of activated CD8+ (15.5%) or
CD4+ (0.9%) T cells remained free of therapy for .46 months, while all patients over the median value had to start
treatment within 26 months.
Conclusions: T cell activation after PHI, more than T cell polyfunctionality or Tregs, is a predictive marker for the control of
viral load and for the time required to start treatment.
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Introduction
Primary infection with the human immunodeficiency virus type-
1 (HIV) is a crucial moment for establishing relationships between
virus and host [1,2,3]. The high plasma viral load (pVL) causes a
relevant and persistent immune activation that can trigger
apoptosis [6–8], and becomes chronic in the absence of a valid
immune response or without efficient antiretroviral therapy. The
immune activation present in this phase is recognizable by typical
changes [4], such as an increase in activated/memory CD8+ T
cells that express CD38, CD45R0, human leukocyte antigen-DR,
and high amounts of cell adhesion molecules, and which can
represent most part of circulating lymphocytes; a decrease in
CD4+ T cells is not always present. High plasma levels of
proinflammatory cytokines have been described, along with
changes in mitochondrial functionality, augmented tendency to
apoptosis and expression of cell death markers (such as CD95) in
almost all white blood cells [5,6,7]. However, no gross alterations
in Vb T-cell repertoire have been found, and the functionality of
the T cell repertoire seems well preserved [8]. In turn, immune
activation can promote viral replication, so facilitating the
infection of other T cells [9,10]. Several studies, including those
in animal models, where primary infection has been experimen-
tally induced and strictly monitored, showed that a strict
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correlation exists between immune activation and progression of
the infection [11].
During PHI, the appearance of virus-specific cytotoxic T lympho-
cytes (CTL) coincides with the decay of viral replication, so that
patients with a high frequency of HIV-specific CTL display a low pVL
and a slow decrease in CD4+ T cell count [12,13]. A significant direct
association between the frequency of CD8+ gag-specific T cells and the
length of AIDS-free period has been observed during chronic infection
[14]. Specific T helper cells are crucial for the anti-HIV immune
response, since they provide help to B and CD8+ cells. A recent study
in SIV-infected macaques has shown that depleting CD4+ during PHI
worsen the infection [15].
HIV preferentially infects HIV-specific CD4+ lymphocytes [16].
The efficacy of a specific immune response is due to CD4+ and CD8+
T cell clones with multiple effectors functions, such as production of
different cytokines and chemokines, activity of costimulatorymolecules,
capacity to perform degranulation and to express cytotoxic molecules
(e.g., perforin) [17,18]. These cells, defined ‘‘polyfunctional’’, are
present at relatively low frequency in HIV+ patients, but at high
frequency in the blood of patients who control the virus, such as long
term non progressors (LTNPs) or ‘‘e´lite controllers’’, where the
presence of HIV-specific polyfunctional CD8+ lymphocytes is
associated with spontaneous control of viral replication [19,20,21,22].
Very few data exist on the polyfunctionality of T cells immediately after
primary infection [23], and we were interesting in investigating this
aspect in a longitudinal manner.
Regulatory T cells (Tregs) have a crucial importance, being a
viral reservoir, as shown by the presence of HIV-DNA in resting
CD4+ Tregs from patients assuming HAART [24]. However,
their role during the infection remains unclear. CD4+ Tregs might
be important for the reduction of immune activation after PHI or
even in chronic infection [25]. During chronic infection they could
cause the deregulation of HIV-specific response [26], so favoring
the progression of the infection, and a decrease of such cells has
been associated to an increase in CD4+ and CD8+ specific
responses to the virus. In chronically infected HIV+ patients,
increased proportions, but reduced absolute numbers of circulat-
ing Tregs were found, and Treg frequency was largely normalized
by HAART [27].
Thus, in order to identify some crucial immunological events
that occur during PHI, we analyzed specific response to viral
antigens such as gag and nef, regulatory CD4+ T cells, and T cell
activation in a group of patients who experienced a well
documented PHI, and have been followed for more than 4 years.
Our main finding is that T cell activation after PHI, more than T
cell polyfunctionality or the presence of Tregs, could be considered
as a predictive marker for the viral setpoint and time required to
treatment.
Materials and Methods
Patients
This longitudinal study enrolled 11 patients (9 males) experi-
encing PHI, who have been followed by the Infectious Diseases
Clinics, University Hospital, Modena (Northern Italy). Median age
of patients at enrolment was 37 years (range: 20–56); 7 acquired
the infection through homosexual intercourses, 4 were heterosex-
ual. All patients had acute PHI documented by positive ELISA
and undefined Western Blot, and were in Fiebig stage III [28].
The date of infection was estimated as about 1 month before
undetermined Western Blot or 2 weeks before symptoms onset.
In these patients, clinical events who took patients to the clinical
observation were: syphilis (1 case), gonorrhea (1), diarrhea (1),
candidiasis (1). Furthermore, one had gallbladder stones, another
psoriasis; such pathologies were not considered related to HIV
infection. All patients came to the medical observation and HIV
testing because they realized to have had a risk because of
unprotected sexual intercourses, that occurred few weeks before
their first visit.
At enrolment, median plasma viral load (VL) was 305,943
copies/mL, median CD4+ T cell count was 816 cells/mL). Viro-
immunological parameters (standard CD4+ T cell count and
quantification of VL) were performed in untreated patients up to
48 months from PHI (specifically at 12, 24, 36, 48 months) or up
to the start of therapy. Chiron branched-DNA was used for
plasma HIV RNA, and a value below 50 copies/mL was
considered undetectable. Immunological analyses were performed
in the first (M1), second (M2), third (M3), fourth (M4) and sixth
(M6) month after infection. The different length of the observation
period, during which no patients took antiretroviral therapy, was
due to different time of enrollment; the longer period of
observation in the survival analysis is due to the fact that during
the time required to perform the analyses here described patients
continued to be followed.
The study has been conducted according to Declaration of
Helsinki principles, and approved by the Modena University
Review Board. All patients gave written informed consent for the
studies here described, according to the Italian laws.
Samples
Peripheral blood mononuclear cells (PBMC) were purified from
EDTA-treated whole blood using Ficoll gradient [29], and
cryopreserved according to standard procedures [30]. Thawed
PBMC were immediately divided in two aliquots: the first part was
stained for phenotype analysis; cells in the second part were rested
at least 4 hours at 37uC, in a 5% CO2 incubator, in complete
RPMI medium [RPMI 1640 supplemented with 10% heat-
inactivated fetal calf serum (FCS), and 1% of each L-glutamine,
sodium pyruvate, non-essential amino acids and antibiotics; all
obtained from Invitrogen, Carlsbad, CA] before stimulation.
PBMC stimulation
After resting and washing, 26106 cryopreserved PBMC were
incubated overnight in presence of a pool of 15-mer peptides
overlapping by 11 amino acids (obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH; final concentration was 2 mg/mL/peptide) spanning
the sequence of HIV-1 gag (123 peptides) and nef (49 peptides),
consensus sequence B. For each sample 0.56106 cells were left
unstimulated as negative control and for each experiment another
0.56106 cells were stimulated with 1 mg/mL Staphylococcus aureus
enterotoxin B (SEB, Sigma-Aldrich, St. Louis, MO) as positive
control. All samples were incubated in presence of the secretion
inhibitors monensin (2.5 mg/mL; Sigma-Aldrich) and brefeldin A
(5 mg/mL; Sigma-Aldrich), the costimulatory monoclonal anti-
bodies (mAb) anti-CD28 (1 mg/mL, R&D Systems, Minneapolis,
MN) and anti-CD49d (1 mg/mL, Serotec, Oxford, UK); anti-
CD107a mAb conjugated with PE-Cy5 (BD Biosciences, San Jose´,
CA) was simultaneously added to detect degranulation [21].
Flow cytometry analysis
Different mAb directly conjugated with different fluorochromes,
obtained from eBioscience (San Diego, CA) (anti-CD154-FITC,
anti-IL-2-PE, anti-IFN-c-PE-Cy7, anti-CD4-APC-Alexa 750, an-
ti-HLA-DR-PE-Cy7, anti-CD38-PE), R&D Systems (anti-CD8-
APC) and Serotec (anti-CD3-Alexa 405) were pre-titrated with the
appropriate buffer before use to identify the optimal combinations
and concentrations [31].
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Cells were stained with the LIVE/DEAD Red Stain Kit
(Molecular Probes, Eugene, OR) and with different mAb for
surface antigens, incubated for 20 minutes at room temperature
and washed with PBS containing 5% FBS and 5 mM EDTA.
Cells were fixed and permeabilized with the ‘‘Cytofix/Cytoperm
buffer set’’ from Becton Dickinson for intracellular cytokine
detection or with the ‘‘Foxp3 Fixation/Permeabilization’’ kit from
eBioscience prior to quantify the intracellular FoxP3 detection.
Samples were finally fixed in PBS+1% paraformaldehyde, kept at
4uC.
A multilaser CyFlow ML flow cytometer (Partec GmbH,
Mu¨nster, Germany) was used to acquire the samples, and the
data were analyzed using FloMax (Partec) and FlowJo v8.8.6
(Tree Star Inc., Ashland, OR, USA) softwares. Single staining
and ‘‘Fluorescence Minus One’’ (FMO) controls were per-
formed, and gates defining the positive and negative expression
of cell surface antigens were combined by boolean gating
strategy, as described [32]. Simplified Presentation of Incred-
ibly Complex Evaluations (SPICE) software (kindly provided
by Dr. Mario Roederer, Vaccine Research Center, NIAID,
NIH) was used to graphically depict polychromatic flow
cytometry data [33]. For T cell function analysis, we put a
threshold of 0.02% on the basis of the distribution of negative
values generated after background subtraction, with a mini-
mum of 10 events [34].
Figure 1. Kinetics of changes in CD4+ T cell count (cell/mL blood, upper panel) and plasma viral load (pVL, number of copies/mL
blood, lower panel) after primary HIV infection. Each patients is represented by a different colour.
doi:10.1371/journal.pone.0050728.g001
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Figure 2. Trends of CD8+ T and CD4+ T cell response to gag- and nef-derived peptides. Boxes indicate median values with 25th and 75th
percentiles, whiskers show minimum and maximum. Figure shows the total response to viral peptides, i.e., the sum of all cells positive for at least one
of the markers studied (IL-2, IFN-c, CD154 and CD107a). Patients were studied at month 1 (M1), month 2 (M2), month 3 (M3), month 4 (M4), and
month 6 (M6) after PHI. The values of nonparametric analysis of variance (Skillings-Mack, and p values) are reported in figures. Stars in graphs indicate
the significant differences of pairwise comparisons between the indicated months, performed by Tukey-Kramer test.
doi:10.1371/journal.pone.0050728.g002
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Figure 3. Characterization of the T cell response to gag-derived peptides. Pie charts show the qualitative composition of total gag-specific
CD4+ or CD8+ T cell response; each pie slice represents the mean proportion of the total CD4+ T cell response contributed by a single functional
pattern, as indicated in the bottom legend. Arcs designed outside the pies represent the fraction of total cells expressing a particular marker,
irrespectively of the positive or negative expression of other markers (blue: CD154; red: CD107a; green: IFN-c; black: IL-2).
doi:10.1371/journal.pone.0050728.g003
Biomarkers of HIV Control after PHI
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Statistical analyses
The time-dependent behavior of T lymphocyte activation,
Tregs and gag- or nef-specific responses were analyzed by the
nonparametric analysis of variance using the Skillings-Mack
test to address the presence of missing data. Tukey-Kramer test
was used for pairwise comparisons between the months.
Differences were considered statistically significant when
p,0.05. Linear regressions were performed to investigate the
associations between viro-immunological parameters (CD4+ T
cell count and pVL), time without therapy and CyFlow data.
Figure 4. Characterization of the T cell response to nef-derived peptides. Pie charts show the qualitative composition of total gag-specific
CD4+ or CD8+ T cell response; each pie slice represents the mean proportion of the total CD4+ T cell response contributed by a single functional
pattern, as indicated in the bottom legend. Arcs designed outside the pies represent the fraction of total cells expressing a particular marker,
irrespectively of the positive or negative expression of other markers (blue: CD154; red: CD107a; green: IFN-c; black: IL-2).
doi:10.1371/journal.pone.0050728.g004
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Survival analysis and Cox proportional hazards model were
also performed. STATA 11 for Mac (College Station, TX) was
used for performing statistical analyses and obtaining part of
the graphics.
Results
PHI cohort and viro-immunological parameters
CD4+ T cell count and pVL were monitored in PHI patients
from the first month up to 4 years after infection. It has to be
underlined that the number of missing data (in terms of analysis not
performed or data not reliable for technical problems), even if
carefully considered by the statistical methods we used, was
negligible in all cases, i.e. ,2%. Figure 1, upper panel, shows that
CD4+ T cell count increased during the first three months, with a
gradual decline in following months (p= 0.0123). In parallel, we
observed a decrease in plasma viral load (p= 0.0607) until the onset
of a stabilization of plasma viral load by the second month of
infection (Figure 1, lower panel). Indeed, at months 2, 3, 4, 6, 12, 24
and 36, viral load was significantly reduced in comparison to M1.
CD107a expression dominates CD4 gag- and nef- specific
response
We studied CD4+ and CD8+ T lymphocyte specific polyfunc-
tional response to gag and nef peptides, considering the production
or expression of molecules such as IFN-c, CD107a, CD154 and IL-
2. We identified both the ‘‘total’’ response, i.e. the sum of all cells
Figure 5. Trends of the Treg frequency (upper panel), absolute
number (middle panel) and activated Treg (lower panel), in the
patients under investigation. Tregs were considered as those cells
that were CD3+,CD4+, positive to FoxP3, highly positive (i.e., bright) to
CD25 and negative to CD127. Boxes indicate median values with 25th
and 75th percentiles, whiskers show minimum and maximum.
doi:10.1371/journal.pone.0050728.g005
Figure 6. Percentages of activated CD4+ (upper panel) and
CD8+ (lower panel) T cells. Activated cells were considered those
expressing high levels of CD38 (CD38 bright) and MHC class II (HLA-DR)
molecules. Boxes indicate median values with 25th and 75th
percentiles, whiskers show minimum and maximum.
doi:10.1371/journal.pone.0050728.g006
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positive for at least one marker (that provides the overall
‘‘frequency’’ of responding cells among T lymphocytes), and the
‘‘qualitative’’ response, which describes the contribution of each
functional pattern to the total specific response. Figure 2 shows a
significant change over time in the percentage of total CD8+ gag-
specific cells, and indicates that CD8 response was higher at M3
than at M1 or M6. The same trend was found considering those
gag-specific CD8+ T lymphocytes that produced IFN-c, or those
that expressed CD107a. We could not detect any significant
variation in the percentage of gag-specific CD4+ T cells, or in the
percentages of both nef-specific CD4+ and CD8+ T cells over time.
Regarding the quality of T cell specific response to gag (Figure 3,
upper part), we found that at all the time points .50% of gag-
specific CD4+ T lymphocytes were CD107a; only a low
percentage was CD154+ or CD154+,IFN-c+. IL-2 production
was detectable only at M6, and in a negligible amount of cells.
Figure 3, lower part, shows that gag-specific CD8+ T lymphocytes
were predominantly CD107a+, and many of them also produced
IFN-c at all time points. IL-2 production was almost never
detected. A significant trend over time was observed in both
CD107a+,IFN-c+ (p = 0.0011) and CD107a single positive
(p = 0.0247) CD8+ T cells, with an increase at M2 and M3 and
a reduction in the following months.
Figure 4 (upper part) shows that also nef-specific CD4+ T cell
response was characterized a relevant expression of CD107a; only
a small amount of cells were able to express CD154 or to produce
IFN-c; IL-2 production was almost never detected. The nef-
specific CD8+ T cell response (Figure 4, lower part) was similar to
that observed for gag: a large proportion of cells were CD107a+
and/or IFN-c+, while a negligible amount of cells expressed
CD154 or produced IL-2.
Treg frequency returns to baseline level 6 months after
HIV infection
We analyzed the frequency and absolute number of Tregs,
defined as CD3+,CD4+,CD25++,CD1272,FoxP3+ cells. As
shown in Figure 5, the frequency of CD4+ T cell with regulatory
phenotype increased over time (upper panel). However, the
absolute number of Treg did not change significantly (middle
panel), as well as the amount of Treg showing an activated
phenotype (i.e., those expressing HLA-DR, lower panel).
Figure 7. Correlation between the level of CD4+ T cell activation status and pVL levels, at all months analyzed. Activated cells were
identified as described in the legend to Figure 6.
doi:10.1371/journal.pone.0050728.g007
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Trend of T cell activation
The activation of CD4+ and CD8+ T cells was studied
taking into account the co-expression of HLA-DR and of high
levels of CD38 (CD38bright), as described [7]. Figure 6 (upper
panel, referred to CD4+, and lower panel, referred to CD8+ T
cells) shows a high level of activation at M1 and M2, and a
significant decrease in the following period.
T cell activation after PHI is a predictive marker for viral
setpoint and length of the period without therapy
Figure 7 shows that a direct correlation was present between the
level of CD4+ T cell activation status and pVL levels, at all months
analyzed. As reported in Figure 8, a direct association was then
found between the frequency of activated T cells (either CD4+ or
CD8+) measured at M2, and plasma viral load, analyzed 1 year
after PHI.
Finally, an inverse association between CD4+ or CD8+ T cell
activation at M2 and M3 and the length of the period free of
therapy was also found (Figure 9).
Activation of CD8+ T cells predicts the length of the
period without therapy
We analyzed the role of CD8+ T cell activation in predicting
the length of the period without treatment, and performed a ‘‘drug
free’’ survival analysis in which we considered the importance of T
cell activation in influencing the length of the period that did not
require any treatment, i.e. from PHI to the failure of virological
control (the time of starting HAART).
Figure 10 (upper part) shows time free of therapy of all our
patients, performed by Kaplan Meyer analysis: 25% of patients
failed (i.e., had to start therapy) within 18 months of HIV
infection, and 50% within 26 months. Five out of 11 patients
were still out of therapy 48 months after PHI.
Two months after PHI, the median percentage of activated
CD8+ T cells was 15.5%, that of CD4+ T cells was 0.9%. By
Cox analysis, we found that activation of CD8+ T cells had a
significant impact on the risk of starting therapy (Hazard
ratio = 1.124 p.|z| = 0.013; 95% Conf. Interval: 1.030–
1.232): the increase in one unit of CD8 activation leads to
an increase in the instantaneous risk of 2.5% to 23%. As shown
in Figure 10 (lower part), we found that all patients with values
of activated CD8+ T cells above the median (5 out of 11) had
to start therapy within 26 months from PHI. Five out of 6
whose values of CD8+ T cell activation were below the median
were still out of therapy for more than 48 months. It is to note
that identical results were obtained considering activated
CD4+ T cells: 80% of patients with less than the median
value remained free of therapy for .48 months, while all
patients above the median had to start treatment within 26
months (not shown).
Discussion
Acute, primary HIV infection has a crucial importance in
determining the entire course of the disease, since in this phase the
immune activation set point predicts the loss of CD4+ T
lymphocytes [2]. Indeed, it has been shown that the level of
CD4+ and CD8+ T cell activation during acute infection is able to
influence the level of HIV viremia, that the level of CD8+ T cells
that express the activation marker CD38 predicts the loss of CD4+
T cells [35], and that not only the reduction of viremia by
antiretroviral treatment reduces immune activation and inflam-
matory phenomena, but also that the reduction of T cell activation
by anti-inflammatory drugs can reduce viremia [36]. A strong
immune activation, that includes the production of proinflamma-
tory cytokines and rapid destruction of CD4+ T cells that reside in
the gut-associated lymphoid tissue, favors massive replication of
the virus and its dissemination in lymphoid tissues. In turn, the
impaired local cellular immunity favors damages to the gastroin-
testinal mucosa, allowing the translocation of microbial products,
including LPS, which contribute to persistent inflammation
through the activation of Toll like receptors.
Furthermore, self-molecules containing the so-called ‘‘damage-
associated molecular pattern’’, or alarmins, that include mito-
chondrial proteins and mitochondrial DNA [37], can further
activate inflammatory pathways and increase the damages [38,39].
Gaining information on the events that occur during primary
infection is thus crucial to find strategies that can either arrest the
initial virus spread, or rescue host cells. To better understand the
importance of immune activation in determining the course of
Figure 8. Association between the frequency of activated T
cells (either CD4+ or CD8+) measured at M2, and plasma viral
load, analyzed 1 year after PHI. Activated cells were identified as
described in the legend to Figure 6.
doi:10.1371/journal.pone.0050728.g008
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HIV infection, we have performed a longitudinal study in a group
of patients in whom several immune parameters were studied for
six months after primary infection, and who were then followed for
up to 5 years.
We analyzed both the subtype and magnitude of specific T
lymphocytes that respond to the viral proteins gag and nef, and
observed an increased level of activity of CD8+ T cells 3 months
after infection. CD4+ T cell specific response against HIV peptides
did not significantly change during the first 6 months and, as
observed in our previous studies on treatment interruption (which
could be considered a sort of secondary acute infection) or by
others (during acute primary infection) was mainly characterized
by cytotoxic features, including the expression of CD107a [21,40].
The efficacy of anti-HIV specific response has been linked to the
‘‘polyfunctionality’’ of specific clones, i.e. to those cells able to exert
simultaneously multiple effectors functions. However, in the first
months after PHI, we could not find truly polyfunctional CD4+
and CD8+ T cells, i.e. those performing 4 functions: indeed, we
could not detect significant amounts of cells able to produce IL-2.
The influence and role of Treg during HIV infection remain
unclear. Discrepant results have been reported, likely depending
on the patient populations, the type and length of treatment,
patient’s age, the time points analyzed, and the way Tregs were
characterized [41,42,43]. Most studies showed that during HIV
infection Treg increase in frequency but decrease in absolute
number, either in blood or in other compartments, likely because
of an increased generation, survival or proliferation in the
periphery, or because of a different redistribution among tissues
[reviewed in 44]. The role played by Tregs during HIV infection is
still poorly understood, as two opposing hypotheses have been
proposed. A detrimental role of Tregs during HIV infection was
suggested based on the evidence that Tregs suppress virus-specific
immune responses. Conversely, Tregs could be beneficial by
limiting immune activation, thus controlling the availability of
HIV targets as well as preventing immune-based pathologies.
Recently, it has been shown that untreated, chronically infected
patients can display a 2-fold increase in the frequency of Tregs
[26]. On the contrary, HIV+ patients defined ‘‘e´lite long-term
Figure 9. Association between CD4+ or CD8+ T cell activation at M2 and M3 and the length of the period free of therapy. Activated
cells were identified as described in the legend to Figure 6.
doi:10.1371/journal.pone.0050728.g009
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nonprogressors’’, with a documented history of at least 12 years of
infection and an undetectable viremia showed had fewer activated
Treg [45].
Very few data are available on these cells in the first stages of
HIV infection. Tregs could be involved in the regulation of the
hyper-activation that occur during PHI, but in our study the
frequency and number of Tregs were not correlated to the control
of the immune activation, to the disease progression, nor to viro-
immunological parameters. Thus, it might be hypothesized that
the time required by the virus (or by the inadequate response to
the virus) to provoke functional or phenotypic Treg alterations is
longer than that we have considered in our study.
Finally, we found high levels of activation in the first two months
after primary infection, that decreased over time. Immune
activation is a well known important and predictive marker in
patients with chronic infection [46], being related to several
phenomena, including loss of CD4+ T cells in the gastrointestinal
tract and the consequent microbial translocation [47,48].
We are aware that our study has some limitations, the first of
which is the limited number of patients followed for a relatively
short time. However, it has to be noted that the enrolment of
patients with acute HIV infection is quite difficult, and we could
only observe a few cases per year. A second limitation of the study
is that the percentage of peripheral blood lymphocytes responding
to specific HIV peptides were quite low, and that in some cases the
individual variability was quite high. These phenomena, along
with the number of patients, were likely responsible for the lack of
any statistical significance of parameters related to T cell
polyfunctionality.
However, here we show that patients who had a lower
frequency of activated CD4+ and CD8+ T lymphocytes in the
first 2 months after primary infection could remain much longer
without antiretroviral therapy, and confirm the importance of the
immune activation set point after primary infection [2]. Since
patients with low immune activation could remain out of therapy –
and thus were able to maintain a relatively high CD4+ T cell
count – for a relatively long period, the identification of this
immune parameter has to be considered when clinicians visit
patients with primary, acute HIV infection. Finally, it is our
opinion that the use of relatively simple flow cytometry methods,
based on the simultaneous detection of no more than 3 or 4
parameters at the single cell level, could be more than sufficient to
identify this biomarker, whose importance is actually not
adequately taken into consideration.
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